clinical trial

[PepGen, Inc.] PepGen, Inc. announced approval by Health Canada of PepGen’s Clinical Trial Application (CTA) authorizing initiation of first-in-human trials of PepGen’s lead Enhanced Delivery Oligonucleotide (EDO) candidate, PGN-EDO51, to treat individuals with Duchenne muscular dystrophy.

[The Ivy Brain Tumor Center] The Ivy Brain Tumor Center at Barrow Neurological Institute announced the opening of a new Phase 0/Ib clinical trial to evaluate AZD1390, an Ataxia telangiectasia mutant kinase inhibitor being developed by AstraZeneca, in patients with recurrent grade IV gliomas.

[PDS Biotechnology Corporation] PDS Biotechnology Corporation announced that the National Cancer Institute (NCI) has achieved the intended enrollment objective of 30 patients in the checkpoint inhibitor refractory arm of the NCI-Led Phase II clinical trial evaluating PDS0101 in combination with two investigational immune-modulating agents in advanced HPV-associated cancers.

[ExCellThera, Inc. (GlobeNewswire, Inc.)] ExCellThera Inc. announced that the first patient has been dosed in its Phase I/II clinical trial of ECT-001 for the treatment of pediatric and young adults with high risk myeloid malignancies.

[Clinical Cancer Research] Researchers investigated the combination of IL-15 with an intratumoral anti-CD40 monoclonal antibody (mAb) in a dual tumor TRAMP-C2 murine prostate cancer model and expanded the regimen to include an anti-PD-1 mAb.

[Clinical Cancer Research] The authors appraise the existing literature and current clinical trial landscape of neoadjuvant therapies in HCC.